BridgeMD
New treatment option for Myopia
Official title Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control
ClinicalTrials.gov ID: NCT06667037
What this study is testing
What is 0.01% Atropine?
0.01% Atropine is an investigational medicine, given as a twice-daily, being studied as a potential treatment for myopia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this multicenter randomized clinical trial is to evaluate the myopia control effect of orthokeratology and 0.01% atropine sequential treatment in children and adolescents, as compared to continuous treatment with orthokeratology.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 8 to 15
You may be able to join if
- Aged 8-15 years old.
- Spherical equivalent refractions (SERs) -0.50 to -6.00 Dioptres (D) and astigmatism less than -1.5 D in both eyes, anisometropia less than 1.5 D.
- Best corrected visual acuity (BCVA) equal to or better than 20/25 in both eyes.
- Bilateral intra-ocular pressure \< 21mmHg.
- Normal binocular and stereoscopic visual function.
You likely can't join if
- Manifest strabismus, except for intermittent tropia.
- Ocular or systemic diseases which may affect vision or refractive error.
- Previous use of myopia control without washout, including atropine, myopia control spectacles, myopia control contact lenses.
- Other contraindications.
See the full eligibility criteria
- Aged 8-15 years old.
- Spherical equivalent refractions (SERs) -0.50 to -6.00 Dioptres (D) and astigmatism less than -1.5 D in both eyes, anisometropia less than 1.5 D.
- Best corrected visual acuity (BCVA) equal to or better than 20/25 in both eyes.
- Bilateral intra-ocular pressure \< 21mmHg.
- Normal binocular and stereoscopic visual function.
- Participants and their guardians' understanding and acceptance of random allocation of grouping.
- Manifest strabismus, except for intermittent tropia.
- Ocular or systemic diseases which may affect vision or refractive error.
- Previous use of myopia control without washout, including atropine, myopia control spectacles, myopia control contact lenses.
- Other contraindications.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 8 years to 15 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.